Cargando…
Efficacy of a Connected Insulin Pen Cap in People With Noncontrolled Type 1 Diabetes: A Multicenter Randomized Clinical Trial
OBJECTIVE: To assess the efficacy of the insulin pen cap Insulclock on improving glycemic control, treatment adherence, and user satisfaction in people with type 1 diabetes. RESEARCH DESIGN AND METHODS: This multicenter, open-label, randomized controlled trial comprised a 4-week run-in phase and a 6...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797789/ https://www.ncbi.nlm.nih.gov/pubmed/36448932 http://dx.doi.org/10.2337/dc22-0525 |
_version_ | 1784860758965747712 |
---|---|
author | Gomez-Peralta, Fernando Abreu, Cristina Fernández-Rubio, Elsa Cotovad, Laura Pujante, Pedro Gaztambide, Sonia Bellido, Diego Menéndez Torre, Edelmiro Ruiz-Valdepeñas, Santiago Bello, Hugo Valledor, Xoan Pérez-González, Jesús Ruiz-Valdepeñas, Luis |
author_facet | Gomez-Peralta, Fernando Abreu, Cristina Fernández-Rubio, Elsa Cotovad, Laura Pujante, Pedro Gaztambide, Sonia Bellido, Diego Menéndez Torre, Edelmiro Ruiz-Valdepeñas, Santiago Bello, Hugo Valledor, Xoan Pérez-González, Jesús Ruiz-Valdepeñas, Luis |
author_sort | Gomez-Peralta, Fernando |
collection | PubMed |
description | OBJECTIVE: To assess the efficacy of the insulin pen cap Insulclock on improving glycemic control, treatment adherence, and user satisfaction in people with type 1 diabetes. RESEARCH DESIGN AND METHODS: This multicenter, open-label, randomized controlled trial comprised a 4-week run-in phase and a 6-week double-arm phase in which participants were randomly assigned into an active or masked mode. RESULTS: Fifty-five participants were evaluable (active group, n = 26, masked group, n = 29). The increase in time in range was higher in the active versus masked group (5.2% vs. −0.8%; P = 0.016). The active group showed a higher reduction in mean glucose, glucose management indicator, time above range, and high blood glucose index. On-time insulin doses increased in the active group and decreased in the masked group. CONCLUSIONS: Insulclock system use was associated with improved glycemic control, glycemic variability, hyperglycemia risk, and treatment adherence in people with uncontrolled type 1 diabetes. |
format | Online Article Text |
id | pubmed-9797789 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Diabetes Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-97977892023-02-11 Efficacy of a Connected Insulin Pen Cap in People With Noncontrolled Type 1 Diabetes: A Multicenter Randomized Clinical Trial Gomez-Peralta, Fernando Abreu, Cristina Fernández-Rubio, Elsa Cotovad, Laura Pujante, Pedro Gaztambide, Sonia Bellido, Diego Menéndez Torre, Edelmiro Ruiz-Valdepeñas, Santiago Bello, Hugo Valledor, Xoan Pérez-González, Jesús Ruiz-Valdepeñas, Luis Diabetes Care Novel Communications in Diabetes OBJECTIVE: To assess the efficacy of the insulin pen cap Insulclock on improving glycemic control, treatment adherence, and user satisfaction in people with type 1 diabetes. RESEARCH DESIGN AND METHODS: This multicenter, open-label, randomized controlled trial comprised a 4-week run-in phase and a 6-week double-arm phase in which participants were randomly assigned into an active or masked mode. RESULTS: Fifty-five participants were evaluable (active group, n = 26, masked group, n = 29). The increase in time in range was higher in the active versus masked group (5.2% vs. −0.8%; P = 0.016). The active group showed a higher reduction in mean glucose, glucose management indicator, time above range, and high blood glucose index. On-time insulin doses increased in the active group and decreased in the masked group. CONCLUSIONS: Insulclock system use was associated with improved glycemic control, glycemic variability, hyperglycemia risk, and treatment adherence in people with uncontrolled type 1 diabetes. American Diabetes Association 2023-01 2022-12-21 /pmc/articles/PMC9797789/ /pubmed/36448932 http://dx.doi.org/10.2337/dc22-0525 Text en © 2022 by the American Diabetes Association https://www.diabetesjournals.org/journals/pages/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/journals/pages/license. |
spellingShingle | Novel Communications in Diabetes Gomez-Peralta, Fernando Abreu, Cristina Fernández-Rubio, Elsa Cotovad, Laura Pujante, Pedro Gaztambide, Sonia Bellido, Diego Menéndez Torre, Edelmiro Ruiz-Valdepeñas, Santiago Bello, Hugo Valledor, Xoan Pérez-González, Jesús Ruiz-Valdepeñas, Luis Efficacy of a Connected Insulin Pen Cap in People With Noncontrolled Type 1 Diabetes: A Multicenter Randomized Clinical Trial |
title | Efficacy of a Connected Insulin Pen Cap in People With Noncontrolled Type 1 Diabetes: A Multicenter Randomized Clinical Trial |
title_full | Efficacy of a Connected Insulin Pen Cap in People With Noncontrolled Type 1 Diabetes: A Multicenter Randomized Clinical Trial |
title_fullStr | Efficacy of a Connected Insulin Pen Cap in People With Noncontrolled Type 1 Diabetes: A Multicenter Randomized Clinical Trial |
title_full_unstemmed | Efficacy of a Connected Insulin Pen Cap in People With Noncontrolled Type 1 Diabetes: A Multicenter Randomized Clinical Trial |
title_short | Efficacy of a Connected Insulin Pen Cap in People With Noncontrolled Type 1 Diabetes: A Multicenter Randomized Clinical Trial |
title_sort | efficacy of a connected insulin pen cap in people with noncontrolled type 1 diabetes: a multicenter randomized clinical trial |
topic | Novel Communications in Diabetes |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797789/ https://www.ncbi.nlm.nih.gov/pubmed/36448932 http://dx.doi.org/10.2337/dc22-0525 |
work_keys_str_mv | AT gomezperaltafernando efficacyofaconnectedinsulinpencapinpeoplewithnoncontrolledtype1diabetesamulticenterrandomizedclinicaltrial AT abreucristina efficacyofaconnectedinsulinpencapinpeoplewithnoncontrolledtype1diabetesamulticenterrandomizedclinicaltrial AT fernandezrubioelsa efficacyofaconnectedinsulinpencapinpeoplewithnoncontrolledtype1diabetesamulticenterrandomizedclinicaltrial AT cotovadlaura efficacyofaconnectedinsulinpencapinpeoplewithnoncontrolledtype1diabetesamulticenterrandomizedclinicaltrial AT pujantepedro efficacyofaconnectedinsulinpencapinpeoplewithnoncontrolledtype1diabetesamulticenterrandomizedclinicaltrial AT gaztambidesonia efficacyofaconnectedinsulinpencapinpeoplewithnoncontrolledtype1diabetesamulticenterrandomizedclinicaltrial AT bellidodiego efficacyofaconnectedinsulinpencapinpeoplewithnoncontrolledtype1diabetesamulticenterrandomizedclinicaltrial AT menendeztorreedelmiro efficacyofaconnectedinsulinpencapinpeoplewithnoncontrolledtype1diabetesamulticenterrandomizedclinicaltrial AT ruizvaldepenassantiago efficacyofaconnectedinsulinpencapinpeoplewithnoncontrolledtype1diabetesamulticenterrandomizedclinicaltrial AT bellohugo efficacyofaconnectedinsulinpencapinpeoplewithnoncontrolledtype1diabetesamulticenterrandomizedclinicaltrial AT valledorxoan efficacyofaconnectedinsulinpencapinpeoplewithnoncontrolledtype1diabetesamulticenterrandomizedclinicaltrial AT perezgonzalezjesus efficacyofaconnectedinsulinpencapinpeoplewithnoncontrolledtype1diabetesamulticenterrandomizedclinicaltrial AT ruizvaldepenasluis efficacyofaconnectedinsulinpencapinpeoplewithnoncontrolledtype1diabetesamulticenterrandomizedclinicaltrial |